Back to Stocks

BLLN

BillionToOne, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

BillionToOne has reached a critical financial inflection point, transitioning from a high-growth startup to a profitable precision diagnostics powerhouse.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic headline growth, BillionToOne's financial foundation remains precarious.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every BLLN filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a classic high-stakes growth story: a company that has successfully scaled its technology and achieved a nominal profit, but remains tethered to rigid debt obligations and complex reimbursement cycles. The leap in revenue and the move to positive net income are undeniable milestones, yet the underlying data reveals a tension between rapid commercial expansion and the stability of the balance sheet. Investors are essentially weighing the company's AI-driven operational gains and a formidable product pipeline against the risk of covenant breaches and deteriorating cash conversion. The success of the J&J partnership and the upcoming MRD test launch will likely be the deciding factors in whether BillionToOne can sustain its current trajectory or if it will succumb to the pressures of its debt structure. Ultimately, the filing highlights a business in a race to outrun its liabilities through hyper-growth. While the operational metrics are trending positively, the lack of remediated internal controls and the volatility of the fair-value debt adjustments suggest that the path to long-term stability will require more than just volume growth; it will require disciplined financial management and consistent payor adoption.

Selected Quarter

Core Takeaway

The company has proven its smNGS platform can scale profitably, but high accounts receivable and strict debt covenants introduce significant volatility.

Investor Lens

The trade-off is between the explosive potential of the oncology pipeline and the binary risk of the Oberland debt covenants.

Watch Next

Q2 trailing six-month net revenue to see if the company meets the $101.8M threshold for the Oberland note.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.25Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 6

First-ever positive Q1 net income of $18 million driven by 84% revenue growth.

earnings beat
90%
bullishMay 6

Gross margin increased to 73% from 64% year-over-year.

margin expansion
70%
bearishMay 6

Increased long-term debt to $90M with strict revenue-based covenants.

debt restructure
60%
neutralMay 6

Ongoing efforts to remediate material weaknesses in internal controls.

management change
30%
bullishMay 6

First-ever positive Q1 net income of $18 million driven by 84% revenue growth.

earnings beat
90%
bullishMay 6

Gross margin increased to 73% from 64% year-over-year.

margin expansion
70%
bearishMay 6

Increased long-term debt to $90M with strict revenue-based covenants.

debt restructure
60%
neutralMay 6

Ongoing efforts to remediate material weaknesses in internal controls.

management change
30%
bullishMay 6

First-ever positive Q1 net income of $18 million driven by 84% revenue growth.

earnings beat
90%
bullishMay 6

Gross margin increased to 73% from 64% year-over-year.

margin expansion
70%
bearishMay 6

Increased long-term debt to $90M with strict revenue-based covenants.

debt restructure
60%
neutralMay 6

Ongoing efforts to remediate material weaknesses in internal controls.

management change
30%
bullishMay 6

First-ever positive Q1 net income of $18 million driven by 84% revenue growth.

earnings beat
90%
bullishMay 6

Gross margin increased to 73% from 64% year-over-year.

margin expansion
70%
bearishMay 6

Increased long-term debt to $90M with strict revenue-based covenants.

debt restructure
60%
neutralMay 6

Ongoing efforts to remediate material weaknesses in internal controls.

management change
30%
bullishMay 6

First-ever positive Q1 net income of $18 million driven by 84% revenue growth.

earnings beat
90%
bullishMay 6

Gross margin increased to 73% from 64% year-over-year.

margin expansion
70%
bearishMay 6

Increased long-term debt to $90M with strict revenue-based covenants.

debt restructure
60%
neutralMay 6

Ongoing efforts to remediate material weaknesses in internal controls.

management change
30%
bullishMay 6

First-ever positive Q1 net income of $18 million driven by 84% revenue growth.

earnings beat
90%
bullishMay 6

Gross margin increased to 73% from 64% year-over-year.

margin expansion
70%
bearishMay 6

Increased long-term debt to $90M with strict revenue-based covenants.

debt restructure
60%
neutralMay 6

Ongoing efforts to remediate material weaknesses in internal controls.

management change
30%
bullishMay 6

First-ever positive Q1 net income of $18 million driven by 84% revenue growth.

earnings beat
90%
bullishMay 6

Gross margin increased to 73% from 64% year-over-year.

margin expansion
70%
bearishMay 6

Increased long-term debt to $90M with strict revenue-based covenants.

debt restructure
60%
neutralMay 6

Ongoing efforts to remediate material weaknesses in internal controls.

management change
30%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing presents a classic high-stakes growth story: a company that has successfully scaled its technology and achieved a nominal profit, but remains tethered to rigid debt obligations and complex reimbursement cycles. The leap in revenue and the move to positive net income are undeniable milestones, yet the underlying data reveals a tension between rapid commercial expansion and the stability of the balance sheet. Investors are essentially weighing the company's AI-driven operational gains and a formidable product pipeline against the risk of covenant breaches and deteriorating cash conversion. The success of the J&J partnership and the upcoming MRD test launch will likely be the deciding factors in whether BillionToOne can sustain its current trajectory or if it will succumb to the pressures of its debt structure. Ultimately, the filing highlights a business in a race to outrun its liabilities through hyper-growth. While the operational metrics are trending positively, the lack of remediated internal controls and the volatility of the fair-value debt adjustments suggest that the path to long-term stability will require more than just volume growth; it will require disciplined financial management and consistent payor adoption.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.